Pierre N, et al. Proteomics highlights common and distinct pathophysiological processes associated with ileal and colonic ulcers in Crohn’s disease. J Crohns Colitis. 2020;14(2):205–15.

Article  PubMed  Google Scholar 

Bewtra M, Kaiser LM, TenHave T, Lewis JD. Crohn’s disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. Inflamm Bowel Dis. 2013;19(3):599–613.

Article  PubMed  Google Scholar 

Fragoulis GE, Liava C, Daoussis D, Akriviadis E, Garyfallos A, Dimitroulas T. Inflammatory bowel diseases and spondyloarthropathies: from pathogenesis to treatment. World J Gastroenterol. 2019;25(18):2162.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sardou HS, Abbaspour M, Akhgari A, Kesharwani P, Sahebkar A. Colon-targeted delivery systems of Budesonide as second-line therapy in inflammatory bowel disease. J Drug Deliv Sci Technol. 2024;93: 105472. https://doi.org/10.1016/j.jddst.2024.105472.

Article  CAS  Google Scholar 

Hajjafari A, et al. Exploring the integration of nanotechnology in the development and application of biosensors for enhanced detection and monitoring of colorectal cancer. Inorg Chem Commun. 2024;164: 112409. https://doi.org/10.1016/j.inoche.2024.112409

Sadr S, et al. Challenges and prospective of enhancing hydatid cyst chemotherapy by nanotechnology and the future of nanobiosensors for diagnosis. Trop Med Infect Dis. 2023;8(11): 494.

Article  PubMed  PubMed Central  Google Scholar 

Ulbrich K, Hola K, Subr V, Bakandritsos A, Tucek J, Zboril R. Targeted drug delivery with polymers and magnetic nanoparticles: covalent and noncovalent approaches, release control, and clinical studies. Chem Rev. 2016;116(9):5338–431.

Article  CAS  PubMed  Google Scholar 

Sardou HS, et al. Comparison of 5-ASA layered or matrix pellets coated with a combination of ethylcellulose and eudragits L and s in the treatment of ulcerative colitis in rats. Int J Pharm. 2023;640: 122981. https://doi.org/10.1016/j.ijpharm.2023.122981.

Article  CAS  PubMed  Google Scholar 

Sardou HS, Vosough PR, Abbaspour M, Akhgari A, Kesharwani P, Sahebkar A. Colon delivery of Resveratrol for the treatment of inflammatory bowel disease. J Drug Deliv Sci Technol. 2024;92: 105315. https://doi.org/10.1016/j.jddst.2023.105315.

Article  CAS  Google Scholar 

Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem Rev. 2016;116(4):2602–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patra JK, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol. 2018;16:1–33.

Article  Google Scholar 

Senapati S, Mahanta AK, Kumar S, Maiti P. Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther. 2018;3(1): 7.

Article  PubMed  PubMed Central  Google Scholar 

Beiranvand M. A review of the biological and pharmacological activities of mesalazine or 5-aminosalicylic acid (5-ASA): an anti-ulcer and anti-oxidant drug. Inflammopharmacology. 2021;29(5):1279–90.

Article  CAS  PubMed  Google Scholar 

Le Berre C, Roda G, Nedeljkovic Protic M, Danese S, Peyrin-Biroulet L. Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. Expert Opin Biol Ther. 2020;20(4):363–78.

Article  PubMed  Google Scholar 

Nielsen OH, Munck LK. Drug insight: aminosalicylates for the treatment of IBD. Nat Clin Pract Gastroenterol Hepatol. 2007;4(3):160–70.

Article  CAS  PubMed  Google Scholar 

Park J, Cheon JH. Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α. Korean J Intern Med. 2022;37(5):895.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qiu X, Ma J, Wang K, Zhang H. Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis. Oncotarget. 2017;8(1):1031.

Article  PubMed  Google Scholar 

Dubey P, Gauttam V, Yadav R. Colon targeting: a novel drug delivery system. NeuroQuantology. 2022;20(13):549.

Article  Google Scholar 

Sharma S, Sinha VR. Current pharmaceutical strategies for efficient site specific delivery in inflamed distal intestinal mucosa. J Controlled Release. 2018;272:97–106.

Article  CAS  Google Scholar 

Sardo HS, Saremnejad F, Bagheri S, Akhgari A, Garekani HA, Sadeghi F. A review on 5-aminosalicylic acid colon-targeted oral drug delivery systems. Int J Pharm. 2019;558:367–79.

Article  Google Scholar 

Nalinbenjapun S, Ovatlarnporn C. Chitosan-5-aminosalicylic acid conjugates for colon-specific drug delivery: methods of preparation and in vitro evaluations. J Drug Deliv Sci Technol. 2020;57: 101397.

Article  CAS  Google Scholar 

Meneguin AB, et al. Nanofiber-boosted retrograded starch/pectin microparticles for targeted 5-aminosalicylic acid delivery in inflammatory bowel disease: in vitro and in vivo non-toxicity evaluation. Carbohydr Polym. 2024;346: 122647. https://doi.org/10.1016/j.carbpol.2024.122647

Article  PubMed  Google Scholar 

Bautzová T, Rabišková M, Lamprecht A. Multiparticulate systems containing 5-aminosalicylic acid for the treatment of inflammatory bowel disease. Drug Dev Ind Pharm. 2011;37(9):1100–9.

Article  PubMed  Google Scholar 

Stavarache CE, et al. 5-aminosalicylic acid loaded chitosan-carrageenan hydrogel beads with potential application for the treatment of inflammatory bowel disease. Polymers. 2021;13(15): 2463.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaffash E, et al. Statistical optimization of alginate-based oral dosage form of 5-aminosalicylic acid aimed to colonic delivery: in vitro and in vivo evaluation. J Drug Deliv Sci Technol. 2019;52:177–88.

Article  CAS  Google Scholar 

Wang N, et al. 5-aminosalicylic acid pH sensitive core-shell nanoparticles targeting ulcerative colitis. J Drug Deliv Sci Technol. 2022;74: 103578.

Article  CAS  Google Scholar 

Bharti S, Mishra S. Controlled drug release behavior of 5-aminosalicylic acid using polyacrylamide grafted oatmeal (OAT-g-PAM): a pH-sensitive drug carrier. Polym Bull. 2019;76:813–24.

Article  CAS  Google Scholar 

Jannin V, Rosiaux Y, Doucet J. Exploring the possible relationship between the drug release of Compritol®-containing tablets and its polymorph forms using micro X-ray diffraction. J Controlled Release. 2015;197:158–64. https://doi.org/10.1016/j.jconrel.2014.11.013.

Article  CAS  Google Scholar 

Abbaspour M, Sadooghi A, Khodaverdi E, Sardou HS, Nokhodchi A. Preparation and evaluation of lipid-based sustained release pellets of chlorpheniramine maleate by the wet extrusion-spheronization method. BioImpacts. 2024.

Patel J, Patel N, Shah S. In vitro controlled release of colon targeted Mesalamine from compritol ATO 888 based matrix tablets using factorial design. Res Pharm Sci. 2009;4(2):63.

CAS  PubMed  PubMed Central  Google Scholar 

Böhm SK, Kruis W. Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis. Clin Exp Gastroenterol. 2014 Sep 23:7:369-83.

Aburahma MH, Badr-Eldin SM. Compritol 888 ATO: a multifunctional lipid excipient in drug delivery systems and nanopharmaceuticals. Expert Opin Drug Deliv. 2014;11(12):1865–83.

Article  CAS  PubMed  Google Scholar 

Sajjadi S, Shayanfar A, Kiafar F, Siahi-Shadbad M. Tacrolimus: physicochemical stability challenges, analytical methods, and new formulations. International Journal of Pharmaceutics: X. 2024;8: 100285. https://doi.org/10.1016/j.ijpx.2024.100285.

Article  CAS  PubMed  Google Scholar 

Adepu S, Ramakrishna S. Controlled drug delivery systems: current status and future directions. Molecules. 2021;26(19): 5905.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Handattu MS, Thirumaleshwar S, Prakash GM, Somareddy HK, Veerabhadrappa GH. A comprehensive review on pellets as a dosage form in pharmaceuticals. Curr Drug Targets. 2021;22(10):1183–95.

Article  CAS